Goelzer Investment Management Cut Its Facebook (FB) Stake; RA Pharmaceuticals (RARX) Shorts Up By 8.59%

Facebook, Inc. (NASDAQ:FB) Logo

RA Pharmaceuticals Inc (NASDAQ:RARX) had an increase of 8.59% in short interest. RARX’s SI was 1.16M shares in December as released by FINRA. Its up 8.59% from 1.07 million shares previously. With 210,500 avg volume, 6 days are for RA Pharmaceuticals Inc (NASDAQ:RARX)’s short sellers to cover RARX’s short positions. The SI to RA Pharmaceuticals Inc’s float is 5.77%. The stock increased 1.42% or $0.23 during the last trading session, reaching $16.46. About 241,590 shares traded. Ra Pharmaceuticals, Inc. (NASDAQ:RARX) has declined 12.52% since December 8, 2017 and is downtrending. It has underperformed by 28.14% the S&P500. Some Historical RARX News: 15/05/2018 – Consonance Capital Management Buys 4.5% of Ra Pharmaceuticals; 25/04/2018 – Ra Pharmaceuticals Announces Presentation of RA101495 SC Phase 2 gMG Clinical Trial Design at the 70th Annual AAN Meeting; 14/03/2018 Ra Pharmaceuticals 4Q Rev $0.00; 26/03/2018 – Ra Pharmaceuticals Presenting at Conference Apr 25; 10/04/2018 – Ra Pharmaceuticals Presenting at Deutsche Bank Conference May 8; 15/05/2018 – Eventide Asset Management Buys 1.2% of Ra Pharmaceuticals; 14/03/2018 – RA PHARMACEUTICALS – EXPECTS CASH AND CASH EQUIVALENTS AT DEC 31, 2017 AND NET PROCEEDS OF OFFERING TO BE SUFFICIENT TO FUND OPERATIONS THROUGH 2019; 25/04/2018 – RA PHARMACEUTICALS INC – REMAINS ON TRACK TO REPORT DATA FROM RA101495 SC PHASE 2 GMG STUDY IN FIRST HALF OF 2019; 18/04/2018 – Ra Pharmaceuticals Appoints John C. King as Chief Commercial Officer; 15/05/2018 – Foresite Capital Mgmt IV Buys 1.4% of Ra Pharmaceuticals

Goelzer Investment Management Inc decreased Facebook Inc (FB) stake by 27.65% reported in 2018Q2 SEC filing. Goelzer Investment Management Inc sold 3,743 shares as Facebook Inc (FB)’s stock declined 15.80%. The Goelzer Investment Management Inc holds 9,793 shares with $1.90M value, down from 13,536 last quarter. Facebook Inc now has $394.92B valuation. The stock decreased 1.58% or $2.21 during the last trading session, reaching $137.42. About 21.16 million shares traded. Facebook, Inc. (NASDAQ:FB) has declined 6.34% since December 8, 2017 and is downtrending. It has underperformed by 21.96% the S&P500. Some Historical FB News: 23/05/2018 – HomeAdvisor to Help Power New Home Services Experience on Facebook Marketplace; 21/03/2018 – Zuckerberg apologizes for Facebook mistakes with user data; 29/03/2018 – POLL-Are Americans taking steps to protect their data after Facebook scandal?; 25/03/2018 – The Facebook-Cambridge Analytica apology tour continues, with full-page ads in major newspapers; 22/03/2018 – CAMBRIDGE ANALYTICA – IN SEPT. 2017 ICO WRITES TO FIRM ABOUT PROCESSING DATA ON U.S. NATIONALS IN UK, PARTIES EXCHANGE NUMEROUS LETTERS; 05/03/2018 – Ex-Trump aide Nunberg says will not comply with Russia probe subpoena; 21/03/2018 – BRITISH PM MAY SAYS RIGHT THAT CAMBRIDGE ANALYTICA, PARENT COMPANY SHOULD BE PROPERLY INVESTIGATED; 26/03/2018 – CARTEL OFFICE SAYS FACEBOOK DATA USAGE IMPROPER: TAGESSPIEGEL; 06/04/2018 – FACEBOOK INC FB.O SUPPORTS HONEST ADS ACT, U.S. PROPOSAL TO REGULATE INTERNET POLITICAL ADS -CEO MARK ZUCKERBERG IN POST; 25/05/2018 – Facebook and Google accused of ignoring GDPR rules

More notable recent Ra Pharmaceuticals, Inc. (NASDAQ:RARX) news were published by: Seekingalpha.com which released: “Ra Pharmaceuticals receives development milestone payment under agreement with Merck – Seeking Alpha” on December 06, 2018, also Seekingalpha.com with their article: “Imprimis Pharmaceuticals and Eyenovia among healthcare gainers; Madrigal Pharmaceuticals leads the losers – Seeking Alpha” published on November 14, 2018, Benzinga.com published: “5 Stocks Moving In Monday’s After-Hours Session – Benzinga” on November 20, 2018. More interesting news about Ra Pharmaceuticals, Inc. (NASDAQ:RARX) were released by: Seekingalpha.com and their article: “Riding Ra Pharmaceuticals – Seeking Alpha” published on July 23, 2018 as well as Benzinga.com‘s news article titled: “64 Biggest Movers From Yesterday – Benzinga” with publication date: November 16, 2018.

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company has market cap of $533.27 million. The companyÂ’s peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. It currently has negative earnings. The Company’s lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria , as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP).

Since June 6, 2018, it had 0 insider purchases, and 82 insider sales for $2.08 billion activity. Another trade for 61,103 shares valued at $10.77M was made by FISCHER DAVID B. on Wednesday, August 29. Another trade for 452,600 shares valued at $87.97 million was made by Zuckerberg Mark on Monday, July 2. Shares for $7.31M were sold by Schroepfer Michael Todd. Cox Christopher K had sold 5,300 shares worth $813,248. Another trade for 750 shares valued at $126,638 was made by Stretch Colin on Wednesday, September 5. Sandberg Sheryl also sold $8.41 million worth of Facebook, Inc. (NASDAQ:FB) on Tuesday, October 23. 9,522 shares were sold by Wehner David M., worth $1.72 million on Wednesday, August 15.

Goelzer Investment Management Inc increased Microsoft Corp (NASDAQ:MSFT) stake by 18,293 shares to 89,798 valued at $8.86 million in 2018Q2. It also upped Ishares Tr (IWD) stake by 4,758 shares and now owns 85,244 shares. Cognizant Technology Solutio (NASDAQ:CTSH) was raised too.

Among 20 analysts covering Facebook (NASDAQ:FB), 15 have Buy rating, 0 Sell and 5 Hold. Therefore 75% are positive. Facebook had 35 analyst reports since June 11, 2018 according to SRatingsIntel. The firm has “Buy” rating by Deutsche Bank given on Wednesday, October 31. The firm earned “Buy” rating on Thursday, July 26 by Stifel Nicolaus. The rating was maintained by Credit Suisse on Monday, October 8 with “Outperform”. The stock of Facebook, Inc. (NASDAQ:FB) has “Overweight” rating given on Friday, July 13 by Barclays Capital. The stock of Facebook, Inc. (NASDAQ:FB) has “Buy” rating given on Wednesday, October 24 by Bank of America. The stock of Facebook, Inc. (NASDAQ:FB) earned “Overweight” rating by JP Morgan on Friday, July 27. On Thursday, July 26 the stock rating was downgraded by Raymond James to “Outperform”. The rating was downgraded by Moffett Nathanson to “Neutral” on Tuesday, September 4. As per Tuesday, October 16, the company rating was maintained by Citigroup. The stock of Facebook, Inc. (NASDAQ:FB) earned “Buy” rating by Argus Research on Thursday, November 1.

Investors sentiment increased to 1.13 in 2018 Q2. Its up 0.04, from 1.09 in 2018Q1. It is positive, as 78 investors sold FB shares while 660 reduced holdings. 187 funds opened positions while 614 raised stakes. 1.66 billion shares or 0.70% more from 1.65 billion shares in 2018Q1 were reported. Parkside Commercial Bank & stated it has 2,166 shares or 0.16% of all its holdings. 633,075 are owned by Blair William & Il. Fin Counselors Inc owns 87,339 shares for 0.78% of their portfolio. Castleark Mngmt Ltd Liability Corp accumulated 219,144 shares. Athena Capital Ltd Llc reported 1,754 shares. Archford Capital Strategies holds 0.27% or 3,929 shares in its portfolio. Wallington Asset Lc reported 2.83% of its portfolio in Facebook, Inc. (NASDAQ:FB). Taconic Capital Advsr Ltd Partnership accumulated 657,000 shares. Davis Capital Ptnrs Lc holds 2.72% in Facebook, Inc. (NASDAQ:FB) or 150,000 shares. Meritage Grp Limited Partnership has 3.72% invested in Facebook, Inc. (NASDAQ:FB). Peregrine Asset Advisers reported 5,686 shares or 0.57% of all its holdings. Loring Wolcott Coolidge Fiduciary Advisors Llp Ma reported 1.23% of its portfolio in Facebook, Inc. (NASDAQ:FB). Ls Investment Ltd Com has invested 0.9% in Facebook, Inc. (NASDAQ:FB). Moreover, Reilly Fincl Advsrs Lc has 0.07% invested in Facebook, Inc. (NASDAQ:FB). 25,801 are held by Wealthtrust Fairport.

Analysts await Facebook, Inc. (NASDAQ:FB) to report earnings on January, 30. They expect $2.16 EPS, down 1.82% or $0.04 from last year’s $2.2 per share. FB’s profit will be $6.21B for 15.91 P/E if the $2.16 EPS becomes a reality. After $1.76 actual EPS reported by Facebook, Inc. for the previous quarter, Wall Street now forecasts 22.73% EPS growth.

Facebook, Inc. (NASDAQ:FB) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.